Yu-Wen Cheng

Yu-Wen Cheng

Auto-generated profile, based on publicly available information

Yu-Wen Cheng

State Key Laboratory of Medical Genomics & Shanghai Institute of Hypertension Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine China, People's Republic of

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2011
Verified
Conference Paper
Closed access
HLHaiyan Liu
Haiyan Liu
YCYuwen Cheng
Yuwen Cheng
ZYZhaohong Yang
Zhaohong Yang
ZZZhanjun Zhang
Zhanjun Zhang
This paper firstly analyzes the security problems which the information systems are facing such as network attacks and attacks by use of communication protocol. Then it proposes a security testing platform basing on interface communication protocols in the light of the characteristics of the communication in information systems. It describes in detail the implementation of this platform. With this method, one can designs test cases to test the security of an information system according to its communication protocol of the hardware interfaces, which can satisfy different requirements of security testing of information systems.

1 October 2018 in Journal Of Hypertension
Verified
Journal Article
Closed access
JZJiu-Chang Zhong
Jiu-Chang Zhong
ZZZhen-Zhou Zhang
Zhen-Zhou Zhang
YCYu-Wen Cheng
Yu-Wen Cheng
JLJing Li
Jing Li
XLXiaoyan Liu
Xiaoyan Liu
GOGavin Oudit
Gavin Oudit
The apelin-APJ system and angiotensin (Ang) II-AT1 pathways have emerged as potent regulators of blood pressure and cardiovascular function. However, the interaction between the apelin and Ang system in myocardial injury remains unclear. The C57/B6 wildtype (WT), apolipoprotein E (ApoE) knockout (KO) and apelinKO mice were randomized to receive either Ang II (1.5 mg.kg-1.d-1) osmotic minipump and /or 100 ug/kg pyr1-apelin-13 for 4 weeks. 1-year aged APLN-/y mice developed increased myocardial hypertrophy and fibrosis with downregulation of ACE2 levels. Importantly, pyr1-apelin-13 reversed Ang II-mediated hypertension, myocardial apoptosis and pathological hypertrophy in both WT and ApoEKO mice. Ang II-induced cardiac fibrosis, dysfunction and altered myocardial ultrastructure were aggravated in the ApoEKO mice which were prevented by pyr1-apelin-13. Importantly, pyr1-apelin-13 attenuated Ang II-mediated pathological effects in ApoE-null hearts associated with increased levels of ACE2 and p-ERK1/2. In cultured neonatal rat cardiomyocytes and cardiofibroblasts, exposure of Ang II decreased ACE2 protein and increased superoxide generation, cellular proliferation and migration, which were rescued by pyr1-apelin-13, Akt and eNOS agonist stimulation. The increased superoxide generation and apoptosis in cultured cardiofibroblasts in response to Ang II were strikingly prevented by pyr1-apelin-13 which was partially reversed by co-treatment with the Akt inhibitor MK2206. Our data provide definitive evidence for cardioprotective roles of pyr1-apelin-13 in aging- and Ang II-mediated pathological remodeling, myocardial fibrosis and dysfunction. Targeting the apelin-APJ pathway represents a novel therapeutic approach against hypertension.

1 October 2017 in JACC
Verified
Journal Article
Closed access
JZJiu-Chang Zhong
Jiu-Chang Zhong
ZZZhenZhou Zhang
ZhenZhou Zhang
HJHaiyan Jin
Haiyan Jin
WWWang Wang
Wang Wang
YCYuWen Cheng
YuWen Cheng
GOGavin Oudit
Gavin Oudit

1 January 2025 in Dermatologic Therapy
Verified
Journal Article
Open access
YWYing-Hsiang Wang
Ying-Hsiang Wang
SLShang-Hung Lin
Shang-Hung Lin
YCYu-Wen Cheng
Yu-Wen Cheng
YYYi-Chien Yang
Yi-Chien Yang
THTing-Jung Hsu
Ting-Jung Hsu
Background: Current therapies for epidermal growth factor receptor inhibitor (EGFRI)–related paronychia demonstrate effectiveness; however, some patients respond poorly and experience recurrent painful granulation tissue, particularly in weight‐bearing areas such as the big toes. Based on promising results from our previous pilot study by Hsu and colleagues, novel kinesiology tape wrapping, which physically shields the inflamed periungual tissue from irritation by the nail plate, has emerged as a potentially effective adjunct therapy. Objectives: This open‐label, randomized‐controlled, single‐center study was aimed to evaluate the efficacy and safety of kinesiology tape wrapping in cancer patients with EGFRI‐related paronychia. Materials and Methods: Eligible participants were assigned to receive either kinesiology tape wrapping in combination with conventional therapies or conventional therapies alone for 12 weeks. Efficacy outcomes, including the reduction of subjective pain assessed by the numerical rating scale (NRS) and the objective single‐digit scoring system for paronychia related to oncologic treatments (single‐digit SPOT), as well as adverse events (AEs), were recorded at baseline and at Weeks 1, 2, 4, 8, and 12 postenrollment. Results: A total of 24 patients were randomized, of which, 22 qualified for analysis. The rate of continuous tape use was 36.3%. At Week 12, pain NRS scores showed no significant differences between groups, while patients treated with continuous or intermittent kinesiology tape wrapping demonstrated notably greater reductions in single‐digit SPOT scores compared to those receiving conventional therapy alone (NRS: 3.27 vs. 2.78, p = 0.586; single‐digit SPOT: 5.32 vs. 1.52, p = 0.022). No serious AEs were reported. Conclusion: Kinesiology tape wrapping is an effective and safe adjunct noninvasive therapy that offers additional benefits in managing EGFRI‐related paronychia. Further studies with longer follow‐ups and improved patient compliance may help fully evaluate its effectiveness in pain reduction. Trial Registration : ClinicalTrials.gov identifier: NCT06411093